Reviewer’s report

Title: Early onset neutropenia: a useful predictor of chemo-sensitivity and favorable prognosis in patients with serous ovarian cancer

Version: 0 Date: 24 Jul 2019

Reviewer: Gennaro Daniele

Reviewer's report:

This is an interesting manuscript facing the longstanding issue if the potential prognostic role of the treatment incident neutropenia in ovarian cancer patients. Nowadays, the prognostic feature of neutropenia is still discussed in this setting since the contrasting literature, published so far.

One advise is to discuss this point more deeply in the discussion including also more recent pieces of evidence (i.e Gynecol Oncol. 2019 Jul;154(1):83-88. doi: 10.1016/j.ygyno.2019.04.012. Epub 2019 Apr 24). In particular, the authors tried to explain the prognostic feature of CIN in the view of the its relationship with the dose of the drug delivered to the patients. They also quote the BSA method to calculate the dose as the main responsible of the variability in the circulating drug levels of chemotherapeutics in patients. On the other hand, it is evident that at least the Cornerstone of the medical treatment of ovarian cancer patients, the carboplatin, is not dosed based on the BSA but on AUC, that is far more accurate than the previous method.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

No

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organisation that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal